52
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          The aim of this study was to explore the impact of augmented creatinine clearance and differing minimum inhibitory concentrations (MIC) on piperacillin pharmacokinetic/pharmacodynamic (PK/PD) target attainment (time above MIC ( fT >MIC)) in critically ill patients with sepsis receiving intermittent dosing.

          Methods

          To be eligible for enrolment, critically ill patients with sepsis had to be receiving piperacillin-tazobactam 4.5 g intravenously (IV) by intermittent infusion every 6 hours for presumed or confirmed nosocomial infection without significant renal impairment (defined by a plasma creatinine concentration greater than 171 μmol/L or the need for renal replacement therapy). Over a single dosing interval, blood samples were drawn to determine unbound plasma piperacillin concentrations. Renal function was assessed by measuring creatinine clearance (CL CR). A population PK model was constructed, and the probability of target attainment (PTA) for 50% and 100% fT >MIC was calculated for varying MIC and CL CR values.

          Results

          In total, 48 patients provided data. Increasing CL CR values were associated with lower trough plasma piperacillin concentrations ( P < 0.01), such that with an MIC of 16 mg/L, 100% fT >MIC would be achieved in only one-third ( n = 16) of patients. Mean piperacillin clearance was approximately 1.5-fold higher than in healthy volunteers and correlated with CL CR ( r = 0.58, P < 0.01). A reduced PTA for all MIC values, when targeting either 50% or 100% fT >MIC, was noted with increasing CL CR measures.

          Conclusions

          Standard intermittent piperacillin-tazobactam dosing is unlikely to achieve optimal piperacillin exposures in a significant proportion of critically ill patients with sepsis, owing to elevated drug clearance. These data suggest that CL CR can be employed as a useful tool to determine whether piperacillin PK/PD target attainment is likely with a range of MIC values.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

          Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48-73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14-24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR, 1.02 and 1.56, respectively; P < .03), with significant interaction with sickness severity status. Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

            The objective of this study was to evaluate the relationship of the predicted pharmacodynamic parameters 24-h area under the inhibitory curve (AUIC=area under the concentration-time curve for 24h of dosing/minimum inhibitory concentration (AUC0-24/MIC) and time above the minimum inhibitory concentration (T>MIC) with clinical and microbiological outcomes in patients with bacteraemia and sepsis treated with cefepime or ceftazidime. Pharmacokinetic and pharmacodynamic parameters were derived for 76 of 107 patients enrolled in two prospective, randomised, clinical trials comparing cefepime with ceftazidime for the treatment of sepsis with bacteraemia, lower respiratory tract infection or complicated urinary tract infection. The relationships between the pharmacodynamic parameters and outcomes were examined. Whilst no significant differences in clinical outcomes were observed between cefepime and ceftazidime, there were significant differences in the pharmacodynamic analysis. Patients with an AUIC> or =250 had significantly greater clinical cure (79% vs. 33%; P=0.002) and bacteriological eradication (96% vs. 44%; P MIC of 100% had significantly greater clinical cure (82% vs. 33%; P=0.002) and bacteriological eradication (97% vs. 44%; P MIC of MIC was <100%.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.

              β-Lactams are routinely used as empirical therapy in critical illness, with extended concentrations above the minimum inhibitory concentration (MIC) of the infecting organism required for effective treatment. Changes in renal function in this setting can significantly impact the probability of achieving such targets. Analysis was made of trough plasma drug concentrations obtained via therapeutic drug monitoring, compared with renal function, in critically ill patients receiving empirical β-lactam therapy. Drug concentrations were measured by means of high-performance liquid chromatography and corrected for protein binding. Therapeutic levels were defined as greater than or equal to MIC and greater than or equal to four times MIC (maximum bacterial eradication), respectively. Renal function was assessed by means of an 8-h creatinine clearance (CLCR). Fifty-two concurrent trough concentrations and CLCR measures were used in analysis. Piperacillin was the most frequent β-lactam prescribed (48%), whereas empirical cover and Staphylococcus species were the most common indications for therapy (62%). Most patients were mechanically ventilated on the day of study (85%), although only 25% were receiving vasopressors. In only 58% (n = 30) was the trough drug concentration greater than or equal to MIC, falling to 31% (n = 16) when using four times MIC as the target. CLCR values ≥ 130 mL/min/1.73 m2 were associated with trough concentrations less than MIC in 82% (P < .001) and less than four times MIC in 72% (P < .001). CLCR remained a significant predictor of subtherapeutic concentrations in multivariate analysis. Elevated CLCR appears to be an important predictor of subtherapeutic β-lactam concentrations and suggests an important role in identifying such patients in the ICU.
                Bookmark

                Author and article information

                Contributors
                a.udy@alfred.org.au
                j.lipman@uq.edu.au
                paul.jarrett@health.qld.gov.au
                Kerenaftali.Klein@qimrberghofer.edu.au
                s.wallis@uq.edu.au
                Kashyap.Patel@monash.edu
                Carl.Kirkpatrick@monash.edu
                peter.kruger@health.qld.gov.au
                david.antibiotics@gmail.com
                m.roberts@uq.edu.au
                j.roberts2@uq.edu.au
                Journal
                Crit Care
                Critical Care
                BioMed Central (London )
                1364-8535
                1466-609X
                30 January 2015
                30 January 2015
                2015
                : 19
                : 1
                : 28
                Affiliations
                [ ]Department of Intensive Care and Hyperbaric Medicine, The Alfred Hospital, Commercial Road, Melbourne, Victoria 3181 Australia
                [ ]Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Butterfield Street, Brisbane, Queensland 4029 Australia
                [ ]Department of Intensive Care Medicine, Royal Brisbane and Women’s Hospital, Butterfield Street, Brisbane, Queensland 4029 Australia
                [ ]Statistics Unit, QIMR Berghofer Medical Research Institute, Herston Road, Brisbane, Queensland 4029 Australia
                [ ]Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Royal Parade, Melbourne, Victoria 3052 Australia
                [ ]Department of Intensive Care Medicine, Princess Alexandra Hospital, Ipswich Road, Brisbane, Queensland 4102 Australia
                [ ]Department of Infectious Diseases, Royal Brisbane and Women’s Hospital, Butterfield Street, Brisbane, Queensland Australia
                [ ]Centre for Clinical Research, The University of Queensland, Butterfield Street Brisbane, Queensland 4029, Australia
                [ ]School of Pharmacy and Medical Sciences, University of South Australia, North Terrace, Adelaide, South Australia 5000 Australia
                Article
                750
                10.1186/s13054-015-0750-y
                4341874
                25632974
                307a7aea-c7ff-467e-9311-df20f427f2c2
                © Udy et al.; licensee BioMed Central. 2015

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 24 October 2014
                : 15 January 2015
                Categories
                Research
                Custom metadata
                © The Author(s) 2015

                Emergency medicine & Trauma
                Emergency medicine & Trauma

                Comments

                Comment on this article